Wanbury Limited (WANBURY) AI Stock Analysis

• Market Cap: ₹8.00B
• Dividend Yield: N/A
• Average Volume (3M): 8.26K
• Price to Earnings (P/E): 12.5
• Beta (1Y): 2.13
• Revenue Growth: 8.92%
• EPS Growth: -5.56%
• Country: IN
• Employees: 1,491
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.50
• Shares Outstanding: 34,939,400
• 10 Day Avg. Volume: 8,584
• 30 Day Avg. Volume: 8,255
• PEG Ratio: -0.63
• Price to Book (P/B): 14.81
• Price to Sales (P/S): 1.46
• P/FCF Ratio: -38.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹245.00 ▲(4.08% Upside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is driven mainly by improving financial performance (revenue and margin recovery) but is held back by high leverage and negative free cash flow. Technicals are supportive on shorter-term moving averages but weakened by a negative MACD and being below the 200-day average, while valuation is broadly reasonable on a mid-range P/E without dividend support.

Positive Factors

Sustained Revenue Growth

A ~16% revenue growth rate indicates the company is regaining top-line momentum across products and markets. Over 2-6 months this supports scale benefits, better utilization of manufacturing capacity and underpins reinvestment in product lines and export expansion.

Negative Factors

High Leverage

Elevated leverage increases interest burden and limits strategic flexibility. Over several months higher debt servicing needs can strain cash flow, constrain capex or M&A options, and heighten vulnerability to input-cost or demand shocks in pharma markets.

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, a...

Read more

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, a...

How the Company Makes Money

Wanbury makes money primarily by (1) selling active pharmaceutical ingredients (APIs) and (2) selling finished dosage formulations (FDF) such as tablets/capsules to distributors, pharmacies, hospitals, and institutional buyers in India and in expo...

Read more

Wanbury makes money primarily by (1) selling active pharmaceutical ingredients (APIs) and (2) selling finished dosage formulations (FDF) such as tablets/capsules to distributors, pharmacies, hospitals, and institutional buyers in India and in expo...

Wanbury Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Jun 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.29B	6.00B	5.74B	4.98B	5.11B	3.87B
Gross Profit	3.40B	3.05B	2.65B	1.89B	2.04B	1.61B
EBITDA	970.25M	798.13M	985.49M	234.91M	1.13B	204.23M
Net Income	501.45M	305.30M	559.56M	-103.96M	814.74M	-126.06M
Balance Sheet
Total Assets	4.57B	4.14B	3.43B	3.04B	3.53B	2.89B
Cash, Cash Equivalents and Short-Term Investments	131.55M	150.63M	34.00M	14.94M	226.56M	101.31M
Total Debt	1.96B	1.77B	1.16B	1.09B	1.08B	2.04B
Total Liabilities	3.49B	3.55B	3.16B	3.36B	3.76B	4.45B
Stockholders Equity	1.07B	592.72M	279.41M	-61.54M	-234.20M	-1.56B
Cash Flow
Free Cash Flow	-247.74M	-229.26M	-134.45M	71.69M	308.65M	122.53M
Operating Cash Flow	-56.53M	261.02M	39.78M	197.97M	405.23M	166.81M
Investing Cash Flow	-152.68M	-511.74M	-166.25M	-88.38M	5.87M	80.44M
Financing Cash Flow	213.44M	257.33M	145.53M	-319.91M	-285.85M	-173.85M

Wanbury Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 235.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 235.4 is below the 20-day moving average (MA) of 239.52, below the 50-day MA of 242.64, and below the 200-day MA of 249.43, indicating a bearish trend. The MACD of -4.90 indicates Positive momentum. The RSI at 43.51 is Neutral, neither overbought nor oversold. The STOCH value of 33.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LINCOLN	78 Outperform	₹10.97B	8.47	―	0.37%	―	―
SAKAR	66 Neutral	₹12.56B	22.21	―	―	24.20%	55.01%
WANBURY	64 Neutral	₹8.00B	12.53	―	―	8.92%	-5.56%
KOPRAN	64 Neutral	₹7.54B	19.44	―	1.96%	-6.96%	-66.75%
THEMISMED	60 Neutral	₹7.60B	22.95	―	0.48%	-18.86%	-150.92%
KILITCH	56 Neutral	₹4.64B	34.53	―	―	32.95%	67.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Wanbury Limited Corporate Events